- Home
- QNRX vs MBIO Comparison
QNRX vs MBIO Comparison
Compare QNRX & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- MBIO
- Stock Information
- Founded
- QNRX 2018
- MBIO 2015
- Country
- QNRX United States
- MBIO United States
- Employees
- QNRX 3
- MBIO N/A
- Industry
- QNRX Medical/Dental Instruments
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- MBIO Health Care
- Exchange
- QNRX Nasdaq
- MBIO Nasdaq
- Market Cap
- QNRX 4.8M
- MBIO 4.7M
- IPO Year
- QNRX N/A
- MBIO N/A
- Fundamental
- Price
- QNRX $8.59
- MBIO $1.61
- Analyst Decision
- QNRX
- MBIO
- Analyst Count
- QNRX 0
- MBIO 0
- Target Price
- QNRX N/A
- MBIO N/A
- AVG Volume (30 Days)
- QNRX 107.3K
- MBIO 117.8K
- Earning Date
- QNRX 11-06-2025
- MBIO 11-07-2025
- Dividend Yield
- QNRX N/A
- MBIO N/A
- EPS Growth
- QNRX N/A
- MBIO N/A
- EPS
- QNRX N/A
- MBIO N/A
- Revenue
- QNRX N/A
- MBIO N/A
- Revenue This Year
- QNRX N/A
- MBIO N/A
- Revenue Next Year
- QNRX N/A
- MBIO N/A
- P/E Ratio
- QNRX N/A
- MBIO N/A
- Revenue Growth
- QNRX N/A
- MBIO N/A
- 52 Week Low
- QNRX $5.01
- MBIO $0.89
- 52 Week High
- QNRX $54.95
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- QNRX 70.88
- MBIO 51.87
- Support Level
- QNRX $7.35
- MBIO $1.54
- Resistance Level
- QNRX $7.79
- MBIO $1.64
- Average True Range (ATR)
- QNRX 0.38
- MBIO 0.09
- MACD
- QNRX 0.13
- MBIO 0.02
- Stochastic Oscillator
- QNRX 46.79
- MBIO 81.52
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.